Scaling solutions, unlocking new frontiers
Empowering global progress through technology
Our Companies
we drive global progress.
MAVOCO delivers software for Connectivity Service Providers and Enterprises who deploy and operate IoT devices with cellular connectivity on a large scale. MAVOCO CMP streamlines, automates and digitalizes all workflows of Connectivity Service Providers from selling to delivering, billing and invoicing of IoT connectivity services.
Freeeway provides global IoT connectivity solutions for enterprises. Their platform enables businesses to manage IoT SIM and eSIM cards, allowing devices to connect across multiple networks worldwide. Additionally, Freeeway offers tools for monetizing IoT services, helping companies create subscription models, manage payments, and automate billing processes.
ecosio provides B2B integration solutions, specializing in EDI, e-invoicing, and supplier integration. Their platform simplifies the digital exchange of documents between businesses and automates data flows. ecosio’s fully managed service improves supply chain efficiency, reduces errors, and ensures compliance with industry standards.
Txture is a cloud transformation platform designed for enterprises and service providers. It streamlines cloud readiness assessments, migration planning, and infrastructure optimization processes. Additionally, Txture delivers data-driven insights to facilitate better decision-making and cloud service comparisons.
a:head bio is a biotech company pioneering drug discovery for central nervous system (CNS) disorders. By leveraging brain organoid technology, they create 3D models that closely replicate human brain tissue, enabling the development of novel therapeutics.
HeartBeat.bio is building the first-ever self-organizing cardiac organoids (“cardioids”) that replicate human heart physiology. Their cutting-edge technology is transforming cardiac drug discovery by offering a more accurate and scalable platform for developing treatments.
Rockfish Bio focuses on promoting healthy aging through the development of senolytic therapies that target age-related diseases.